Cereno Scientific publishes Annual Report for 2023
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for common and rare cardiovascular disease, today published their Annual Report for 2023.Cereno Scientific’s Annual Report for 2023 is available on the Company’s website, both in Swedish and in English. The Annual General Meeting (AGM) will be held in Gothenburg, Sweden, on April 16, 2024. The notice and other documents related to the AGM are available on the Company's website. For further information, please contact: Henrik Westdahl, Director IR & Communications Email: henrik.